<DOC>
	<DOCNO>NCT02629965</DOCNO>
	<brief_summary>This multi-centre , randomised , double-blinded , active-controlled , 2-way cross trial assess effect daily administration orally inhale tiotropium + olodaterol FDC tiotropium ( deliver RESPIMAT Inhaler ) pulmonary function ( lung hyperinflation ) , exercise capacity ( 6-minute walk distance ) physical activity 6 week treatment Japanese patient Chronic Obstructive Pulmonary Disease .</brief_summary>
	<brief_title>Comparing Efficacy Tiotropium + Olodaterol Fixed Dose Combination ( FDC ) Over Tiotropium Improvement Lung Hyperinflation , Exercise Capacity Physical Activity Japanese COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : All patient must sign informed consent consistent ICHGCP guideline prior participation trial , include medication washout restriction . All patient must diagnosis chronic obstructive pulmonary disease ( COPD ) must meet follow spirometric criterion : Patients must relatively stable airway obstruction postbronchodilator Forced expiratory volume one second ( FEV1 ) &lt; 80 % predict normal postbronchodilator FEV1/forced vital capacity ( FVC ) &lt; 70 % Visit 1 . Male female patient , age &gt; = 40 year . Patients must current exsmokers smoke history 10 pack year . Patients never smoke cigarette must exclude . Patients score modify Medical Research Council ( mMRC ) &gt; = 1 . Patients walk &lt; 400 meter 6MWT score modified Borg &gt; = 4 end 6 minute walk test ( 6MWT ) Visit 2 . Patients must able perform technically acceptable pulmonary function test ( spirometry ) , use physical activity monitor must able complete 6MWT study period require protocol . Patients must able inhale medication competent manner RESPIMAT Inhaler meter dose inhaler . Exclusion criterion : Patients significant disease COPD ; significant disease define disease , opinion investigator , may put patient risk participation study , influence result study cause concern regard patient 's ability participate study . Patients clinically relevant abnormal baseline haematology , blood chemistry , urinalysis creatinine &gt; x2 ULN exclude regardless clinical condition ( repeat laboratory evaluation conduct deemed necessary investigator ) . Patients current document diagnosis asthma . For patient allergic rhinitis atopy , source documentation require verify patient asthma . Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>